Arena Gains Evidence To Address FDA Concerns About Lorcaserin, But More Still Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech released some new results regarding the safety of lorcaserin as it continues to pursue FDA approval for the drug.
You may also be interested in...
Clinical Stage Biotechs For Sale?
The oversized price tag attached to the recent acquisition of Pharmasset by Gilead has caused many to wonder how the take-out fits into historical patterns – or if it’s as big an outlier as it seems.
Orexigen Resurrects Contrave With New Trial Agreement With FDA
The biotech breathes new life into its obesity program now that it has reached agreement with FDA on a two-year cardiovascular safety study for Contrave.
Orexigen Resurrects Contrave With New Trial Agreement With FDA
The biotech breathes new life into its obesity program now that it has reached agreement with FDA on a two-year cardiovascular safety study for Contrave.